1851 — Richard Spruce documents ayahuasca/caapi in the Amazon
Richard Spruce · Royal Botanic Gardens, Kew (field expedition, Rio Uaupes / Rio Negro, Brazil)
British botanist Richard Spruce observed Tukano people of the Rio Uaupes preparing a psychoactive beverage from a vine he named Banisteria caapi (later reclassified Banisteriopsis caapi in 1931). He collected specimens and recorded preparation and effects; his account was published posthumously in 'Notes of a Botanist on the Amazon and Andes' (1908). This is the first scientific/ethnobotanical documentation of the ayahuasca complex, the traditional vehicle through which orally-active DMT reaches the brain (later understood via MAO inhibition by harmala alkaloids).
Why it matters: Establishes the ethnobotanical prehistory of DMT science: the plant admixtures Western chemistry would only decode a century later. Predates the identification of DMT itself by 80 years.
1931 — First chemical synthesis of DMT (Richard Manske)
Richard Helmuth Fredrick Manske · National Research Council of Canada / University of Manitoba
German-Canadian chemist Richard Manske first synthesized N,N-dimethyltryptamine as one of several methyltryptamines, reported in 'A synthesis of the methyltryptamines and some derivatives,' Canadian Journal of Research 5(5):592-600. At the time DMT's psychoactivity, and its later-discovered natural occurrence in plants and animals, were entirely unknown; it was a routine synthetic-chemistry result.
Why it matters: The molecular origin point of DMT science. DMT existed as a defined synthetic compound for 25 years before anyone knew it was psychoactive, and for 15 years before it was found in nature.
1946 — First isolation of DMT from a plant (nigerine, from Mimosa)
Oswaldo Gonçalves de Lima · Instituto de Pesquisas Agronomicas de Pernambuco, Brazil
Brazilian chemist and microbiologist Oswaldo Gonçalves de Lima isolated an alkaloid he named 'nigerina' (nigerine) from the root bark of jurema preta (Mimosa tenuiflora, syn. Mimosa hostilis), the plant basis of the traditional 'vinho da jurema.' The compound's identity was only unequivocally resolved later: in 1959 American chemists (working from a Mimosa sample) identified N,N-DMT, and nigerine is now generally regarded as having been an impure DMT extract, making this the first detection of DMT in any plant.
Why it matters: First natural occurrence of DMT ever found, connecting the 1931 lab curiosity to real botany and to indigenous jurema/ayahuasca practice. The delayed confirmation is itself an honesty point: 'nigerine' was named before its structure was proven.
1952 — Transmethylation / 'endogenous psychotogen' hypothesis of schizophrenia proposed
Humphry Osmond and John Smythies · St George's Hospital, London (later Weyburn, Saskatchewan)
Osmond and Smythies proposed that schizophrenia might arise from an aberrant endogenous methylation producing a mescaline-like hallucinogen in the body ('Schizophrenia: a new approach,' Journal of Mental Science 98:309-315). This 'transmethylation hypothesis,' and the related adrenochrome hypothesis, framed decades of search for an internally-made psychotogen — a search that would soon focus on DMT once it was found in human fluids.
Why it matters: The intellectual engine behind the 1960s endogenous-DMT/schizophrenia program. Historically pivotal for launching biochemical psychiatry, but the specific claim that DMT causes schizophrenia was never substantiated and is now largely abandoned.
1956 — First human psychopharmacology of DMT (Szara self-experiments, Budapest)
Stephen (Istvan) Szara · National Institute for Nervous and Mental Diseases (Lipotmezo), Budapest, Hungary
After oral DMT produced no effect, Hungarian chemist-psychiatrist Stephen Szara synthesized DMT and self-administered it by intramuscular injection, discovering intense, short-lived (about one hour) hallucinogenic effects; he then studied it in about 20 volunteers. Published as 'Dimethyltryptamin: its metabolism in man; the relation of its psychotic effect to the serotonin metabolism,' Experientia 12(11):441-442. Szara is often called the 'father of DMT.'
Why it matters: The first demonstration that DMT is psychoactive in humans, and the first that it is inactive orally but active parenterally — the pharmacokinetic fact that explains both injection studies and why ayahuasca needs an MAO inhibitor.
1961 — An enzyme that can make DMT identified in mammalian tissue (Axelrod)
Julius Axelrod · National Institute of Mental Health (NIMH), USA
Nobel laureate Julius Axelrod reported an N-methyltransferase activity in rabbit lung that could methylate tryptamine to N-methyltryptamine and DMT using S-adenosylmethionine ('Enzymatic formation of psychotomimetic metabolites from normally occurring compounds,' Science 134:343). This showed the body possesses biochemical machinery capable, in principle, of producing DMT endogenously.
Why it matters: Gave the transmethylation hypothesis a concrete enzymatic candidate and launched the endogenous-DMT enzymology later associated with INMT. That an enzyme CAN make DMT in vitro does not establish that meaningful amounts are made in the living human brain — a distinction still unresolved.
1965 — DMT detected in human blood and urine (Franzen & Gross)
Franz Franzen and Heinz Gross · Germany
Franzen and Gross reported the detection of tryptamine, N,N-dimethyltryptamine, bufotenine (5-OH-DMT) and 5-methoxytryptamine in human blood and urine ('Tryptamine, N,N-dimethyltryptamine, N,N-dimethyl-5-hydroxytryptamine and 5-methoxytryptamine in human blood and urine,' Nature 206:1052). This was among the first claims that DMT is an endogenous human compound.
Why it matters: Turned DMT into a putative endogenous human molecule and fueled the schizophrenia-transmethylation research wave. Caveat: a later systematic review (Barker et al. 2012) concluded that many early quantitative detections, including high reported levels, were likely analytical errors — so the FACT of endogenous DMT is now better supported by modern LC-MS/MS work than by these 1960s assays.
1971 — DMT scheduled: US Controlled Substances Act & UN Convention on Psychotropic Substances
United States Congress; United Nations · US federal government; United Nations Office at Vienna
DMT was placed in the most restrictive control category: Schedule I under the US Controlled Substances Act (a status it has held since the law took effect), and included in the UN Convention on Psychotropic Substances, signed in Vienna on 21 February 1971. Schedule I / Schedule I designations assert high abuse potential and no accepted medical use, imposing the legal framework that would make later human research require special DEA/regulatory approval.
Why it matters: The regulatory event that effectively froze legal human DMT research for roughly two decades and shaped why Strassman's 1990s trials were landmark 'firsts since scheduling.' Also created the legal ambiguity around plant ayahuasca that courts and treaties still navigate.
1994 — First new-era DEA-approved human DMT trials (Rick Strassman, UNM)
Rick J. Strassman · University of New Mexico School of Medicine, Albuquerque
From 1990-1995 Strassman ran the first US government-approved (DEA/FDA) human psychedelic trials in a generation, administering roughly 400 doses of intravenous DMT to about 60 volunteers. The dose-response and tolerance work was published in peer-reviewed psychiatry journals ('Dose-response study of N,N-dimethyltryptamine in humans,' Archives of General Psychiatry 51(2):85-97, 1994) and later popularized in the book 'DMT: The Spirit Molecule' (2001), which advanced the (explicitly speculative) hypothesis that the pineal gland releases DMT at birth, death, and mystical states.
Why it matters: Reopened legal clinical psychedelic research in the US and produced the first modern controlled human DMT pharmacology. Load-bearing distinction: the peer-reviewed dose-response data are established science; the 'spirit molecule' pineal narrative is Strassman's hypothesis and remains unproven.
2001 — First placebo-controlled human pharmacology of ayahuasca (Jordi Riba)
Jordi Riba (with Manel Barbanoj) · Autonomous University of Barcelona / Hospital de Sant Pau, Spain
Riba conducted the first double-blind, placebo-controlled clinical trials of ayahuasca in healthy volunteers, characterizing subjective effects, tolerability, cardiovascular effects, pharmacokinetics and neurophysiology using standardized freeze-dried ayahuasca ('Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers,' Psychopharmacology 154:85-95, 2001; PhD thesis 'Human Pharmacology of Ayahuasca,' 2003).
Why it matters: Brought the orally-active, MAOI-potentiated route of DMT into rigorous clinical pharmacology and demonstrated it could be given safely under controlled conditions — the scientific foundation of modern ayahuasca research. Riba (1968-2020) is the field's central figure for ayahuasca.
2012 — Critical review re-examines all claims of endogenous DMT in humans (1955-2010)
Steven A. Barker, Ethan H. McIlhenny, Rick Strassman · Louisiana State University; University of New Mexico; Cottonwood Research Foundation
Barker and colleagues systematically reviewed 69 studies reporting DMT, bufotenine and 5-MeO-DMT in human blood, urine and CSF from 1955-2010, assessing methods and reliability. They concluded that many early studies reporting relatively high concentrations were probably in error, that correlations built on them were likely incorrect, and that rigorous modern analytical methods were needed to settle whether and where DMT is made in the human body ('A critical review of reports of endogenous psychedelic N,N-dimethyltryptamines in humans: 1955-2010,' Drug Testing and Analysis 4:617-635).
Why it matters: The honesty anchor for the whole endogenous-DMT question: it separates the credible signal from decades of unreliable measurement and reframed the 'DMT is in us' claim as needing modern proof rather than assumed fact.
2013 — DMT and precursors detected in rat pineal gland microdialysate (Cottonwood/Strassman group)
Steven A. Barker, Jimo Borjigin, Izabela Lomnicka, Rick Strassman · Louisiana State University; University of Michigan; Cottonwood Research Foundation / University of New Mexico
Using LC-MS/MS on microdialysate sampled from the pineal gland of living rats, the group detected DMT alongside its precursors and metabolites and melatonin-pathway compounds ('LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate,' Biomedical Chromatography 27:1690-1700).
Why it matters: First modern, analytically rigorous evidence that DMT is present in the pineal region of a living mammal — partially vindicating the pineal-DMT idea for rats, while NOT demonstrating psychoactive-level release, a role in consciousness, or that the human pineal does the same.
2016 — Nichols' definitive 'Psychedelics' pharmacology review
David E. Nichols · University of North Carolina / Purdue University
David Nichols published 'Psychedelics' in Pharmacological Reviews (68:264-355), a comprehensive, heavily-cited synthesis of the medicinal chemistry, receptor pharmacology (notably 5-HT2A agonism), and neuroscience of serotonergic hallucinogens including DMT.
Why it matters: Became the canonical modern reference framing DMT within classic-psychedelic pharmacology and the 5-HT2A mechanism, and set the rigorous, skeptical tone that distinguishes the scientific literature from popular mythology.
Source: D. E. Nichols — Psychedelics, Pharmacological Reviews 68(2):264-355 (2016) ↗
2018 — 'DMT and the pineal gland: separating fact from myth' (Nichols)
David E. Nichols · University of North Carolina
Nichols directly critiqued the popular claim that the pineal gland secretes psychoactive amounts of DMT at birth, in dreams, and at death ('N,N-dimethyltryptamine and the pineal gland: separating fact from myth,' Journal of Psychopharmacology 32(1):30-36). He noted the pineal weighs under 0.2 g and produces only ~30 micrograms/day of melatonin, making it implausible that it could generate psychedelic quantities of DMT.
Why it matters: The field's clearest published rebuttal of the 'pineal spirit molecule' folklore. Essential for an honesty charter: it marks exactly where evidence stops and speculation begins.
2019 — Neural correlates of the DMT experience mapped with EEG (Imperial College)
Christopher Timmermann, Robin Carhart-Harris, and colleagues · Centre for Psychedelic Research, Imperial College London
In a placebo-controlled study of intravenous DMT, the Imperial group recorded multivariate EEG and linked brain-activity changes to subjective experience over time ('Neural correlates of the DMT experience assessed with multivariate EEG,' Scientific Reports 9:16324). DMT reduced alpha/beta oscillatory power and increased spontaneous signal diversity, with delta/theta emergence tracking the peak of the experience.
Why it matters: First detailed human neuroimaging signature of the DMT state, launching the modern Imperial DMT neuroscience program and grounding subjective reports in measurable brain dynamics.
2019 — DMT shown to be biosynthesized and released in rat brain at neurotransmitter-like levels
Jon G. Dean, Jimo Borjigin, Steven Barker, Rick Strassman, and colleagues · University of Michigan (Borjigin lab); LSU; Cottonwood/UNM
The group showed INMT and AADC transcripts co-localize in rat and human brain regions (cortex, pineal, choroid plexus), and measured extracellular DMT in the cortex of normal behaving rats at concentrations comparable to serotonin and dopamine ('Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain,' Scientific Reports 9:9333). DMT persisted even after pinealectomy, indicating non-pineal brain sources.
Why it matters: Strongest modern evidence that the mammalian brain can synthesize and release DMT endogenously — but in RATS. Whether the human brain does the same, and what function it serves, remains open; the paper raises rather than settles the human question.
2023 — Human brain effects of DMT via simultaneous EEG-fMRI
Christopher Timmermann, Robin Carhart-Harris, and colleagues · Centre for Psychedelic Research, Imperial College London
Combining EEG and fMRI during intravenous DMT, the team showed DMT flattens the brain's functional hierarchy and increases global connectivity, especially in association cortex, correlating with the intensity and immersive quality of the experience ('Human brain effects of DMT assessed via EEG-fMRI,' PNAS 120(13):e2218949120).
Why it matters: Highest-resolution account to date of how DMT reorganizes human brain activity, advancing mechanistic models (e.g., relaxed high-level priors / hierarchy collapse) of the psychedelic state.
2023 — Extended-state DMT: continuous target-controlled infusion ('DMTx')
Emma Eckernas, Christopher Timmermann, Lisa X. Luan, and colleagues · Imperial College London; University of Gothenburg
Researchers modeled and then implemented a bolus-plus-constant-infusion protocol to hold DMT at a chosen psychedelic intensity, overcoming its very short half-life to prolong the state ('Optimized infusion rates for N,N-dimethyltryptamine...,' British Journal of Clinical Pharmacology, 2023; and the extended-DMT trial reported in Journal of Psychopharmacology, 2024). Volunteers sustained the DMT state for extended periods across escalating target levels.
Why it matters: Turns a ~10-minute experience into a controllable, extendable state — enabling steady-state neuroscience and, potentially, therapeutic 'dose-duration' control. This 'DMTx' capability is a genuine methodological milestone of the current renaissance.
2023 — Therapeutic pivot: SPL026 (DMT) Phase IIa for major depressive disorder (Small Pharma)
Small Pharma (Carol Routledge and colleagues); investigators incl. David Erritzoe · Small Pharma Ltd; Imperial College / clinical sites
Small Pharma reported positive topline results from the first placebo-controlled Phase IIa trial of a short-duration psychedelic — intravenous SPL026 (DMT) with supportive therapy — in patients with moderate/severe major depressive disorder, meeting its primary endpoint with a rapid and durable reduction in depressive symptoms and no drug-related serious adverse events (announced Jan/Mar 2023; full trial later published in Nature Medicine, 2025).
Why it matters: Marks DMT's transition from consciousness-science curiosity to clinical antidepressant candidate, and the first controlled evidence that a very short psychedelic can produce meaningful antidepressant effects. Early-stage: efficacy claims await larger Phase IIb/III confirmation.
2023 — DMT beyond psychiatry: Phase 1 trials for stroke and anxiety (Algernon; Cybin)
Algernon Pharmaceuticals / Algernon NeuroScience; Cybin (and Entheon Biomedical) · Centre for Human Drug Research, Leiden, Netherlands (both programs)
Algernon NeuroScience dosed the first subject in a Phase 1 trial of intravenous AP-188 (DMT) for ischemic stroke, invoking DMT's sigma-1 receptor activity and proposed neuroplasticity/neuroprotection. In parallel, Cybin advanced CYB004, a deuterated DMT, into first-in-human then Phase 2 trials for generalized anxiety disorder (building on a DMT study acquired from Entheon Biomedical).
Why it matters: Extends the therapeutic hypothesis for DMT beyond depression into neurology (stroke/neuroprotection) and other anxiety indications, and shows the commercialization wave (novel salts, deuterated analogs, patents). Efficacy for these indications is unproven; these are early safety/exploratory studies.
✦Popular claims vs. the evidence
Widely-repeated statements about DMT, each with its real evidentiary status. Where a claim is unproven, it is labeled unproven — not dismissed and not endorsed.
| Claim | Status | What the evidence actually shows |
|---|---|---|
| The pineal gland releases a flood of DMT at death to produce near-death and out-of-body experiences. | unproven | No evidence that large amounts of DMT are released near death in humans. This is a hypothesis popularized by Strassman, explicitly critiqued by Nichols (2018), who noted the human pineal is too small (<0.2 g, ~30 ug/day melatonin) to plausibly make psychedelic quantities of DMT. Where DMT is made in humans and what it does remain unknown. |
| The human pineal gland is proven to produce DMT. | unproven | DMT has been detected in RAT pineal microdialysate (Barker 2013) and rat brain shows biosynthesis at neurotransmitter-like levels (Dean/Borjigin 2019), and INMT/AADC transcripts occur in human brain regions. But direct demonstration of DMT synthesis by the living HUMAN pineal, at meaningful levels, has not been shown. Rat findings do not equal human proof. |
| Endogenous DMT causes schizophrenia (transmethylation hypothesis). | unproven | The 1950s-60s transmethylation hypothesis (Osmond & Smythies) drove decades of research but was never substantiated. Barker et al. (2012) found many early studies reporting high DMT levels in patients were likely analytical errors. No reliable correlation between endogenous DMT and schizophrenia has been established. |
| DMT levels are far higher in schizophrenic patients' blood and urine. | contested | The historical positive findings (from the 1960s-70s 'pink spot' era) were mostly produced with insufficiently specific methods. A systematic modern re-evaluation concluded most early high-concentration reports were probably in error. The question is not settled by those data. |
| The brain releases DMT during REM sleep / dreaming. | unproven | No human study has demonstrated DMT release tied to REM/dreaming. This is speculation extrapolated from the pineal hypothesis; it has not been shown experimentally. |
| Everyone meets the same 'entities' on DMT because those beings/realms exist independently of the brain. | untestable / ontologically neutral | Recurring entity encounters and shared phenomenological features are documented in surveys and neurophenomenology, but whether these entities have mind-independent existence is not a scientifically testable claim. The archive reports the experiences as reported and takes no metaphysical position. Neural correlates of the DMT state are measurable (Timmermann 2019, 2023); the ontological status of its contents is not adjudicable by those data. |
| 'The Spirit Molecule' names a proven biological/spiritual function of DMT. | unproven | 'The Spirit Molecule' is the title/framing of Strassman's 2001 popular book and an evocative hypothesis, not an established scientific function. DMT's receptor pharmacology (5-HT2A agonism, sigma-1 activity) is well characterized; a 'spiritual function' is interpretation, not demonstrated biology. |
| Goncalves de Lima proved in 1946 that jurema's active alkaloid was DMT. | contested | He isolated and named 'nigerine' in 1946, but its identity as N,N-DMT was not unequivocally confirmed until later work (circa 1959) on Mimosa samples. Nigerine is now generally regarded as an impure DMT extract; the 1946 event is best described as the first plant detection of what was later confirmed to be DMT, not a 1946 proof. |
| DMT is a proven, approved treatment for depression / stroke / anxiety. | unproven | As of 2025 no DMT product has regulatory approval. SPL026 met a Phase IIa endpoint for major depression (promising but early), and stroke (Algernon AP-188) and anxiety (Cybin CYB004) programs are in early-phase safety/exploratory trials. Efficacy for any indication awaits larger confirmatory trials. |